PMID- 14757293
OWN - NLM
STAT- MEDLINE
DCOM- 20041007
LR  - 20221207
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 63
IP  - 3
DP  - 2004 Mar
TI  - Combination therapy with rosiglitazone and glibenclamide compared with upward 
      titration of glibenclamide alone in patients with type 2 diabetes mellitus.
PG  - 213-23
AB  - AIM: To compare the efficacy of combination therapy using rosiglitazone (8 mg per 
      day) and glibenclamide (7.5 mg per day) with upward titration of glibenclamide as 
      monotherapy (maximum dose=15 mg per day) in reducing HbA(1c) levels over 26 weeks 
      in patients with type 2 diabetes mellitus (T2DM). METHODS: Three hundred and 
      forty patients with T2DM inadequately controlled (FPG > or =7.0 and < or =15.0 
      mmol/l) on glibenclamide 7.5 mg per day were randomised to either additional 
      treatment with rosiglitazone 8 mg per day or up-titration of the glibenclamide 
      dose (maximum dose=15 mg per day). RESULTS: After 26 weeks, treatment with 
      rosiglitazone combination reduced HbA(1c) by 0.81% (P<0.0001) and FPG by 2.4 
      mmol/l (P<0.0001) compared with glibenclamide monotherapy. HOMA-S and HOMA-B 
      increased by 12 and 28%, respectively (P<0.0001 for both) with combination 
      compared with glibenclamide monotherapy. With rosiglitazone combination and 
      glibenclamide monotherapy, total cholesterol: HDL ratio reduced by 5 and 13%, 
      triglycerides reduced by 6 and 2%, and FFAs reduced by 15 and 8%, respectively. 
      Both treatments were well tolerated and had predictable safety profiles. 
      CONCLUSION: For patients inadequately controlled on glibenclamide, addition of 
      rosiglitazone provides significantly improved glycaemic control compared with 
      uptitration of glibenclamide. This may be preferable to continued monotherapy 
      with higher doses of glibenclamide.
FAU - Kerenyi, Zsuzsa
AU  - Kerenyi Z
AD  - Fourth Department of Medicine, Szent Imre Hospital, Budapest, Hungary.
FAU - Samer, Holger
AU  - Samer H
FAU - James, Rachel
AU  - James R
FAU - Yan, Ying
AU  - Yan Y
FAU - Stewart, Murray
AU  - Stewart M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (C-Peptide)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Placebos)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Triglycerides)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - SX6K58TVWC (Glyburide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - C-Peptide/blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Fasting
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Glyburide/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Rosiglitazone
MH  - Thiazolidinediones/adverse effects/*therapeutic use
MH  - Triglycerides/blood
EDAT- 2004/02/06 05:00
MHDA- 2004/10/08 09:00
CRDT- 2004/02/06 05:00
PHST- 2004/02/06 05:00 [pubmed]
PHST- 2004/10/08 09:00 [medline]
PHST- 2004/02/06 05:00 [entrez]
AID - S0168822703002262 [pii]
AID - 10.1016/j.diabres.2003.09.009 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2004 Mar;63(3):213-23. doi: 
      10.1016/j.diabres.2003.09.009.